BCL2 and adrenal cortex carcinoma: We independently confirmed the synergistic effects of the BCL-2 inhibitors Venetoclax and Navitoclax and of the mTOR inhibitor Everolimus (Fig. 6B and C; Supplementary Fig. S3A) in the ACC cell lines.